Supernus Pharmaceuticals (SUPN) Net Cash Flow (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Net Cash Flow data on file, last reported at $56.4 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $56.4 million, up 21.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $70.5 million (up 34.37% YoY), and the FY2025 annual result was $60.6 million, up 1158.31% from the prior year.
• Net Cash Flow rose to $56.4 million in Q1 2026 per SUPN's latest filing, from -$22.9 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $369.1 million in Q1 2023 and troughed at -$437.5 million in Q2 2023.
• A 5-year average of -$1.0 million and a median of -$11.3 million in 2024 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 520.75% in 2023 and fell as far as 858.05% in 2023.
• A 5-year view of Net Cash Flow shows it stood at -$18.4 million in 2022, then dropped by 8.49% to -$19.9 million in 2023, then surged by 288.94% to $37.7 million in 2024, then slumped by 160.87% to -$22.9 million in 2025, then surged by 346.13% to $56.4 million in 2026.
• Business Quant data shows SUPN's Net Cash Flow at $56.4 million in Q1 2026, -$22.9 million in Q4 2025, and $8.1 million in Q3 2025.